Arcus Biosciences, Inc. Form 4 Filings

Arcus Biosciences president Juan C. Jaen reported open-market sales of 68,569 shares of common stock on July 9–10, 2026, executed indirectly through a trust. The trades, made under a Rule 10b5-1 trading plan, were at weighted-average prices around $28.61–$30.05 per share. He continues to hold substantial positions, including 378,291 shares held directly and more than 800,000 shares held indirectly via a trust.

Arcus Biosciences, Inc. president Juan C. Jaen, through a trust, sold a total of 31,431 shares of common stock of Arcus Biosciences in open-market transactions over June 22–24. The reported weighted average sale prices ranged from about $27.03 to $29.66 per share.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. After the most recent sale, the trust associated with Jaen held 890,809 shares indirectly, while a separate entry shows 378,291 shares held directly as of June 22. Footnotes note that the indirect holdings include unvested RSUs and 1,279 shares acquired through the company’s Employee Stock Purchase Plan.

Arcus Biosciences director Nicole Lambert reported equity awards consisting of restricted stock units and stock options. On June 11, 2026, she received 5,700 shares of Common Stock as a grant, bringing her direct holdings to 43,000 shares.

She was also granted options to buy 16,900 shares at an exercise price of $23.30 per share, expiring on June 10, 2036. Both the 5,700 restricted stock units and the 16,900 options vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and each will become fully vested if the company undergoes a change in control.

Arcus Biosciences director Patrick Machado received new equity awards. On June 11, 2026 he was granted 5,700 shares of common stock in the form of restricted stock units, which vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and become fully vested if the Company undergoes a change in control.

He was also granted stock options for 16,900 shares at an exercise price of $23.30 per share, expiring on June 10, 2036, with the same vesting and change‑in‑control acceleration terms. Following these awards, Machado directly holds 44,300 shares of Arcus Biosciences common stock. These are compensation-related grants rather than open‑market purchases.

Arcus Biosciences, Inc. director Yasunori Kaneko reported new equity awards and updated indirect holdings of Common Stock. On June 11, 2026, he received 5,700 restricted stock units, which vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and accelerate upon a change in control. He also received a stock option for 16,900 shares at an exercise price of $23.30 per share, vesting on the same schedule and also accelerating upon a change in control. Following these awards, he holds 25,700 shares of Common Stock directly, and indirect holdings include 174,681 shares by trust, 505,050 shares by Kaneko Capital, LLC, and 252,524 shares by Kaneko Investments, LLC. A footnote notes 13,300 previously reported RSUs vested on June 11, 2026 and were transferred to his trust.

Arcus Biosciences General Counsel Carolyn C. Tang exercised stock options to acquire 34,090 shares of common stock at $2.574 per share on June 11, 2026. This was a derivative exercise, not an open-market purchase.

The fully vested option was completely exercised, leaving no remaining options from this grant. Following the transaction, Tang directly holds 184,607 common shares, which include 1,783 shares purchased through the company’s Employee Stock Purchase Plan and unvested RSU awards.

Arcus Biosciences director David L. Lacey received new equity awards on common stock. He was granted 5,700 restricted stock units, increasing his direct common stock holdings to 76,652 shares after the award.

He also received a stock option for 16,900 shares with an exercise price of $23.30 per share, expiring on June 10, 2036. Both the RSUs and the option vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and each will become fully vested if the company is subject to a change in control.

Arcus Biosciences director Kathryn E. Falberg reported new equity awards and updated her share holdings. She received 5,700 shares of Common Stock as restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and accelerate upon a change in control.

Falberg also received a stock option covering 16,900 shares at an exercise price of $23.30 per share, with the same vesting and change-in-control terms. After these awards, she holds 44,300 shares directly and 132,106 shares indirectly through a trust, which now includes 30,000 shares reclassified from direct ownership.

Arcus Biosciences director Antoni Ribas reported new equity awards and updated his holdings. He received 5,700 shares of Common Stock as restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and they fully vest if the company undergoes a change in control. He was also granted a stock option for 16,900 shares at an exercise price of $23.30 per share, with the option vesting on the same schedule and also accelerating upon a change in control. Following these awards, Ribas directly owns 44,300 Common Stock shares and holds an additional 8,553 shares indirectly through a trust.

Arcus Biosciences director Andrew J. Perlman received new equity awards as part of his compensation. He was granted 5,700 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and will fully vest if the company undergoes a change in control. Following this grant, he holds 48,325 Common Shares directly. Perlman also received a stock option covering 16,900 shares at an exercise price of $23.30 per share, vesting on the same schedule and expiring on June 10, 2036, with full vesting upon a change in control. These awards are compensation-related grants rather than open-market purchases or sales.

Arcus Biosciences, Inc. Chief Accounting Officer Alexander Azoy reported an open-market sale of 2,562 shares of common stock. The shares were sold at a weighted average price of $25.7704 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Azoy directly holds 39,581 shares, which include unvested restricted stock unit grants.

Arcus Biosciences director Antoni Ribas reported a routine insider update. He made a bona fide gift of 5,050 shares of Common Stock, described as a gift to family members for estate planning purposes. This transfer is a disposition but not a market sale, with no price received.

After the gift, Ribas directly holds 38,600 Common Stock shares, and separately has 8,553 shares held indirectly by a trust. A footnote notes that his indirect holdings include the unvested portion of his RSU grants, indicating ongoing equity exposure through both direct and indirect ownership.

Arcus Biosciences Chief Financial Officer Robert C. Goeltz II reported an open-market sale of 7,763 shares of common stock at $25.63 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, he holds 84,161 shares, including unvested RSUs.

Arcus Biosciences Chief Medical Officer Markus Richard received new equity awards. On January 23, 2026, he was granted 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues to serve the company.

He was also granted a stock option for 96,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, contingent on his continued service. After these grants, he beneficially owned 89,647 shares of common stock directly and 96,000 stock options.

Arcus Biosciences Chief Executive Officer Terry J. Rosen reported new equity awards. On January 23, 2026, he received 79,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues to serve the company.

On the same date, he was also granted stock options for 315,000 shares of Arcus common stock with an exercise price of $22.13 per share. The options become exercisable in 48 equal monthly installments after January 1, 2026, contingent on his continued service. After these transactions, Rosen beneficially owned 2,236,409 shares of common stock directly, including unvested RSUs.

Arcus Biosciences, Inc. reported new equity awards for President Juan C. Jaen. On January 23, 2026, he received 31,000 shares of common stock as restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning December 15, 2026, contingent on his continued service, bringing his directly held common stock to 377,012 shares, including unvested RSUs. He also received a stock option for 126,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, and all 126,000 option shares are reported as directly owned. In addition, 922,240 shares of common stock are reported as indirectly owned through a trust.

Arcus Biosciences granted equity awards to its General Counsel, Carolyn C. Tang. She received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, conditioned on her continued service with the company.

She was also granted a stock option for 96,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, also subject to continued service. Following these transactions, Tang directly beneficially owns 148,734 shares of common stock, which includes unvested RSUs, and holds 96,000 stock options.

Arcus Biosciences granted Chief Financial Officer Robert C. Goeltz II new equity awards. On 01/23/2026, he received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.

He was also granted a stock option to buy 96,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. Following the RSU grant, he beneficially owned 91,924 shares of common stock directly, which includes unvested RSUs.

Arcus Biosciences Chief Accounting Officer Alexander Azoy received new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he was granted 21,050 shares of Common Stock as restricted stock units at a price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.

On the same date, he also received a stock option to buy 14,050 shares of Common Stock at an exercise price of $22.13 per share, with no cost for the grant itself. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. After these transactions, he beneficially owned 39,581 shares of Common Stock, including unvested RSUs, held directly.

Arcus Biosciences Chief Operating Officer receives new equity awards. On January 23, 2026, COO Jennifer Jarrett was granted 31,000 shares of common stock in the form of restricted stock units, which vest in four equal annual installments beginning on December 15, 2026, as long as she continues serving the company. She also received a stock option covering 126,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to her continued service. Following these grants, she directly holds 224,024 shares of common stock, including unvested RSUs, and 126,000 stock options.

Arcus Biosciences Chief Executive Officer and director Terry J. Rosen reported a charitable gift of company stock. On 01/08/2026, Rosen donated 35,000 shares of Arcus Biosciences, Inc. common stock, coded as a charitable gift transaction. The shares were transferred at a reported price of $0 per share, consistent with a non-cash donation. After this gift, Rosen beneficially owned 2,157,409 shares of common stock, which the disclosure notes includes the unvested portion of his restricted stock unit grants. This filing updates the market on Rosen’s current direct equity stake in the company.

Arcus Biosciences president Juan C. Jaen reported indirect sales of Arcus Biosciences common stock held by a trust associated with him. On January 5, 2026, the trust sold 29,670 shares at a weighted average price of $21.34, 2,053 shares at a weighted average price of $22.34, and 100 shares at $23.20, under a Rule 10b5-1 trading plan adopted on August 8, 2025.

Following these transactions, the trust continued to hold 922,240 shares of Arcus Biosciences common stock. Jaen also reported 346,012 shares held directly, which include the unvested portion of his restricted stock unit grants.

Arcus Biosciences, Inc. Chief Financial Officer reported a sale of company stock in a routine insider transaction. On 12/31/2025, the reporting person sold 6,552 shares of Arcus Biosciences common stock at a price of $23.38 per share. After this transaction, the insider beneficially owned 67,924 shares of common stock in the company.

The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule, helping separate trading decisions from day-to-day nonpublic information about the business.

Arcus Biosciences, Inc. reported an insider share transfer by its Chief Executive Officer and director. On 12/30/2025, the reporting person transferred 2,400 shares of common stock at a reported price of $0, using transaction code G. After this transaction, the individual directly beneficially owns 2,192,409 shares of Arcus common stock.

According to the notes, the 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, while retaining voting and dispositive power over all of the transferred shares.

Arcus Biosciences, Inc. reported that its general counsel sold company stock in mid-December 2025 in transactions related to restricted stock unit (RSU) vesting. On December 16, 2025, 7,658 shares of common stock were sold at a weighted average price of $21.8843, leaving 131,544 shares beneficially owned afterward. On December 17, 2025, a further 6,810 shares were sold at a weighted average price of $22.1595, resulting in 124,734 shares beneficially owned. The filing explains that these sales were made by the issuer on the reporting person’s behalf to cover tax withholding obligations triggered by RSU vesting under an equity administration policy implemented on May 22, 2025, and are described as non‑discretionary trades. The remaining holdings include one share acquired through the company’s employee stock purchase plan and the unvested portion of the reporting person’s RSU grants.

Arcus Biosciences Chief Medical Officer reports automatic share sales and corrects equity award vesting terms. On 12/16/2025 and 12/17/2025, the CMO sold 5,052 and 4,494 shares of common stock, respectively, as reported sales to cover tax withholding obligations tied to vesting restricted stock units. The filing states these sales occurred automatically under the company’s equity administration policy and were not discretionary trades. After these transactions, the CMO beneficially owned 70,141 and then 65,647 shares, including unvested RSUs. The document also corrects the vesting schedule for awards granted on February 10, 2025: RSUs vest in four equal annual installments beginning December 15, 2025, and stock options become exercisable in 48 equal monthly installments after January 31, 2025, subject to continued service.

Arcus Biosciences’ Chief Accounting Officer reported routine stock sales over three days in December 2025. On December 16, 17, and 18, 2025, the officer reported selling 2,376, 2,113, and 4,343 shares of common stock, respectively, at weighted average prices of $21.8843, $22.1595, and $22.2458 per share.

According to the footnotes, the first two sales were made by the issuer on the officer’s behalf to cover tax withholding obligations from vesting restricted stock units and occurred automatically under the company’s equity administration policy implemented on May 22, 2025. The sales on December 18, 2025 were effected under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these transactions, the officer beneficially owned 18,531 shares, including unvested RSUs.

Arcus Biosciences, Inc. reported insider share sales by its Chief Financial Officer related to restricted stock unit (RSU) vesting. On 12/16/2025, the CFO sold 6,702 shares of common stock at a weighted average price of $21.8843 per share, and on 12/17/2025, sold an additional 5,960 shares at a weighted average price of $22.1595 per share.

The company states these shares were sold by the issuer on the CFO’s behalf to cover tax withholding obligations arising from the vesting of previously granted RSUs, under an equity administration policy implemented on May 22, 2025, and that the sales were not discretionary trades. Following these transactions, the CFO beneficially owned 80,436 shares after the first sale and 74,476 shares after the second sale, which include the unvested portion of her RSU grants.

Arcus Biosciences, Inc. reported that its Chief Operating Officer, a company officer, sold shares of common stock in mid-December 2025 in connection with restricted stock unit (RSU) vesting. On 12/16/2025, 11,225 shares were sold at a weighted average price of $21.8843, leaving 203,007 shares beneficially owned. On 12/17/2025, 9,983 shares were sold at a weighted average price of $22.1595, leaving 193,024 shares beneficially owned.

The filing explains that these sales were made by the issuer on the officer’s behalf solely to cover tax withholding obligations tied to the vesting of previously granted RSUs, and occurred automatically under the company’s equity administration policy rather than as discretionary trades. The remaining beneficial ownership figure includes unvested portions of the officer’s RSU grants.

Arcus Biosciences’ president reports automatic tax‑related share sales tied to RSU vesting. On 12/16/2025 and 12/17/2025, the reporting officer sold 11,225 and 9,983 shares of Arcus Biosciences common stock, respectively, at weighted average prices of $21.8843 and $22.1595 per share. The filing explains these sales were made by the company on the officer’s behalf to cover tax withholding obligations when certain previously granted restricted stock units vested, under an equity administration policy implemented on May 22, 2025, and were not discretionary trades. After these transactions, the officer beneficially owns 346,012 shares directly, including unvested RSUs, and 954,063 shares indirectly through a trust.

Arcus Biosciences, Inc. Chief Executive Officer and director reported automatic sales of company stock mainly to cover taxes tied to equity awards. On 12/16/2025, 28,947 shares of common stock were sold at a weighted average price of $21.8843, and on 12/17/2025, 25,744 shares were sold at a weighted average price of $22.1595, both coded as open-market sales. According to the footnotes, these transactions were carried out by the issuer on the executive’s behalf to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units and were not discretionary trades by the executive.

After these transactions, the reporting person beneficially owned 2,194,809 shares of Arcus Biosciences common stock, which includes 236 shares acquired on November 30, 2025 through the company’s employee stock purchase plan and the unvested portion of outstanding RSU grants.

Arcus Biosciences, Inc. reported an insider stock sale by its president. A Form 4 filing shows that on 12/04/2025, the executive sold 82,997 shares of Arcus common stock at a weighted average price of $24.7069 per share, in multiple trades within a price range of $24.35 to $25.15. After these transactions, the reporting person beneficially owned 954,063 shares indirectly through a trust and 367,220 shares directly. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025, which is designed to allow pre-arranged trading independent of day-to-day market conditions.

Arcus Biosciences Chief Accounting Officer reports option exercise and share sale. On 11/26/2025, the officer exercised a stock option to acquire 1,900 shares of Arcus Biosciences common stock at $13.33 per share and on the same date sold 1,900 shares at $26 per share under a Rule 10b5-1 trading plan. After these transactions, the officer directly beneficially owned 27,363 shares of common stock and 9,500 stock options with a $13.33 exercise price, which are scheduled to become exercisable in 48 equal monthly installments after January 1, 2025 and expire on January 22, 2035.

Arcus Biosciences (RCUS) Chief Financial Officer reports stock sale under pre-arranged plan. The CFO sold 5,000 shares of Arcus Biosciences common stock on 11/26/2025 at a price of $25 per share in an open market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 87,138 shares of Arcus Biosciences common stock in direct ownership. The filing states that the sale was made under a Rule 10b5-1 trading plan, which is a pre-established program intended to allow insiders to sell shares according to set instructions.

Arcus Biosciences, Inc. (RCUS) reported insider stock sales by its President, who is an officer of the company. On November 17, 2025, a trust associated with the reporting person sold 37,114 shares of common stock at a weighted average price of $20.2274, and a further 7,836 shares at a weighted average price of $20.713. On November 18, 2025, the trust sold an additional 5,050 shares at a weighted average price of $19.75. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, the reporting person beneficially owned 1,037,060 shares indirectly through a trust and 367,220 shares directly.

Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer. On 11/07/2025, the officer exercised 50,291 stock options at $1.2276 per share and sold 50,291 common shares at a $18.9709 weighted average price under a Rule 10b5-1 trading plan. After these trades, the officer directly held 214,232 common shares. The filing notes the sales occurred across multiple trades between $18.59 and $19.42. Remaining derivative holdings include 80,583 stock options with an expiration date of 03/14/2027.

Arcus Biosciences (RCUS): The company’s President reported an open‑market sale of 4,314 shares of common stock on 10/30/2025 at a weighted average price of $20.3175, executed under a Rule 10b5‑1 trading plan adopted on August 12, 2024.

Following the transaction, the reporting person beneficially owned 1,087,060 shares indirectly (by trust) and 367,220 shares directly. The price reflected multiple trades between $20.12 and $20.63.

Arcus Biosciences (RCUS) reported insider transactions by its President. On 10/28/2025, an indirect trust sold 19,019 shares at a weighted average price of $20.1874 (range $20.00–$20.36). On 10/29/2025, the trust sold 47,675 shares at $20.4894 (range $20.00–$20.99), 29,365 shares at $21.5279 (range $21.02–$22.01), and 800 shares at $22.0441 (range $22.035–$22.055), all pursuant to a Rule 10b5-1 plan adopted on August 12, 2024. Following the reported transactions, beneficial holdings were 1,091,374 shares indirect (by trust) and 367,220 shares direct.

Arcus Biosciences (RCUS) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO sold 5,000 shares of common stock at $20 per share, coded as an open market sale (S).

Following the transaction, the officer beneficially owns 92,138 shares, held directly. The filing notes the sales were made under a Rule 10b5-1 trading plan adopted on March 7, 2023, which pre-schedules trades.

Insider transactions by Arcus Biosciences (RCUS): The company's Chief Operating Officer exercised stock options and sold a total of 50,292 shares across two dates, 10/06/2025 and 10/08/2025. The exercises used options with a $1.2276 exercise price, adding 50,292 underlying shares to the reporting pool. Sales were executed at weighted-average prices of $14.5441 and $15.0458, and the filings state these transactions were made pursuant to a Rule 10b5-1 trading plan. Following the transactions the reporting person beneficially owned 214,232 shares, which includes 863 shares bought via the employee stock purchase plan on 05/30/2025. The options exercised were fully vested and exercisable, with expiration dates noted as 03/14/2027.

Arcus Biosciences (RCUS) insider sale by Chief Accounting Officer. The reporting person sold 2,831 shares of Arcus common stock on 09/29/2025 at $13.00 per share, leaving beneficial ownership of 27,363 shares after the transaction. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted on June 6, 2025. The filing was executed by an attorney-in-fact on 09/30/2025. This report discloses a planned, executed disposition by a senior financial officer that reduced their holdings by approximately 9.4% of their pre-sale position.